What's Going On With Fulcrum Therapeutics Stock Tuesday?

Benzinga02-24

Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock fell Tuesday as the company announced results from its Phase 1b trial for pociredir in sickle cell disease. The company released initial results from the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613748522?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/24/Genetic-Research-And-Biotech-Science-Con_1.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2026-02-24 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613748522","market":"hk","top_or_hot":-1,"title":"What's Going On With Fulcrum Therapeutics Stock Tuesday?","media":"Benzinga","content":"<div>\n<p>Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock fell Tuesday as the company announced results from its Phase 1b trial for pociredir in sickle cell disease.\nThe company released initial results from the ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50816196/whats-going-on-with-fulcrum-therapeutics-stock-tuesday\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Fulcrum Therapeutics Stock Tuesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Fulcrum Therapeutics Stock Tuesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-24 22:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/02/50816196/whats-going-on-with-fulcrum-therapeutics-stock-tuesday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock fell Tuesday as the company announced results from its Phase 1b trial for pociredir in sickle cell disease.\nThe company released initial results from the ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50816196/whats-going-on-with-fulcrum-therapeutics-stock-tuesday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/02/50816196/whats-going-on-with-fulcrum-therapeutics-stock-tuesday","article_id":"2613748522","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/24/Genetic-Research-And-Biotech-Science-Con_1.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50816196/whats-going-on-with-fulcrum-therapeutics-stock-tuesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613748522","pubTimestamp":1771944480,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Fulcrum Therapeutics Inc.  stock fell Tuesday as the company announced results from its Phase 1b trial for pociredir in sickle cell disease.The company released initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir.Mean absolute fetal hemoglobin  increased by 9.9% at six weeks of treatment with pociredir , increasing from a baseline of 7.1% to 16.9%.In the recent announcement on Tuesday, Fulcrum reported that mean absolute fetal hemoglobin  increased by 12.2% at Week 12 in the 20 mg cohort compared to 8.6% in the 12 mg cohort, with 58% of patients achieving HbF levels of 20% or more.The proportion of HbF-containing red blood cells  increased from a mean of 31% at baseline to 63% at Week 12 , indicating progression toward pan-cellular HbF induction.F-cells are more resistant to sickling and hemolysis because of HbF-mediated inhibition of sickle hemoglobin  polymerization. The company on Tuesday highlighted that Higher proportions of F-cells are as","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","FULC":"Fulcrum Therapeutics"},"translate_title":"Fulcrum Therapeutics股票周二发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FULC":1.5},"content_text":"Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock fell Tuesday as the company announced results from its Phase 1b trial for pociredir in sickle cell disease.\nThe company released initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir.\nMean absolute fetal hemoglobin (HbF) increased by 9.9% at six weeks of treatment with pociredir (vs. 5.6% at week six and 8.6% at week 12 in the 12 mg cohort), increasing from a baseline of 7.1% to 16.9%.\nIn the recent announcement on Tuesday, Fulcrum reported that mean absolute fetal hemoglobin (HbF) increased by 12.2% at Week 12 in the 20 mg cohort compared to 8.6% in the 12 mg cohort, with 58% of patients achieving HbF levels of 20% or more.\nThe proportion of HbF-containing red blood cells (F-cells) increased from a mean of 31% at baseline to 63% at Week 12 (n=10), indicating progression toward pan-cellular HbF induction.\nF-cells are more resistant to sickling and hemolysis because of HbF-mediated inhibition of sickle hemoglobin (HbS) polymerization. The company on Tuesday highlighted that Higher proportions of F-cells are associated with improved RBC health.\nThe trial demonstrated improvements in markers of hemolysis and anemia, with no serious adverse events reported, which could indicate a strong safety profile for pociredir.\nOne patient discontinued on Day 1 due to an unrelated Grade 5 serious adverse event and is excluded from the PD analysis set but is included in the safety analysis set.\nFulcrum plans to report additional data from the 20 mg cohort, including through the 4-week follow-up period, at a future medical conference.\nFulcrum plans to initiate a potential registration-enabling trial in the second half of 2026, following discussions with regulators.\nFulcrum also plans to engage with the European Medicines Agency in mid-2026 to obtain protocol assistance and feedback on the design of the next trial.\nIn addition, Fulcrum is activating sites for an open-label extension trial for participants in the PIONEER trial to evaluate the safety and durability of response with pociredir.\nThe company ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities, providing a projected cash runway through 2029.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $12.80. Recent analyst moves include:\nFULC Price Action: Fulcrum Therapeutics shares were down 10.01% at $9.80 at the time of publication on Tuesday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613748522","isCrawlerRequest":true}